Erlotinib dose-adjusted for smoking status effective as first treatment for head and neck cancer

Head and neck cancers respond well to the anti-cancer drug erlotinib when it is administered before surgery and a stronger dose is given to patients who smoke, according to a study presented at the Multidisciplinary Head and Neck Cancer Symposium, sponsored by AHNS, ASCO, ASTRO and SNM.

Read the whole article on Physorg

More from Physorg